BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 26080934)

  • 21. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
    Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
    Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.
    Ang JX; Lee WY; Tay SK
    Ann Acad Med Singap; 2023 May; 52(5):259-267. PubMed ID: 38904523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [To analyse the histopathological results of patients with HPV16/18 positive and colposcopic suspicious lesions].
    Zhang JX; Zheng TP; Liu J; Wang QX; Zhan YX; Zhang ZY
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jul; 52(7):467-472. PubMed ID: 28797154
    [No Abstract]   [Full Text] [Related]  

  • 26. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical analysis of the infection with human papillomavirus in women].
    Li AX; Yin R; Zhong BY; Hao F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):49-52. PubMed ID: 16816863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.
    Chiappetta C; Puggioni C; Lendaro E; Cacciotti J; Zaralli R; Migliore G; Bellardini P; Petrozza V; Della Rocca C; Di Cristofano C
    Int J Clin Exp Pathol; 2015; 8(12):16089-96. PubMed ID: 26884886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of human papillomavirus genotyping testing in the diagnosis of cervical intraepithelial neoplasia].
    Liu G; Yu L; Song H; Mi R; Chen Y
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jun; 49(6):446-50. PubMed ID: 25169638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen].
    Liu ZH; Lin W; Wang YY; Wu B; Yuan SX; Yao JL; Zhao XS; Chen B; Qiao YL; Zhao FH; Chen W; Hu SY
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):757-763. PubMed ID: 30392340
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
    Kares S; Veijalainen O; Kholová I; Tirkkonen M; Vuento R; Huhtala H; Tuimala V; Mäenpää J; Kujala P
    APMIS; 2019 Nov; 127(11):710-716. PubMed ID: 31403733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
    Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions.
    Álvarez-Paredes L; Santibañez M; Galiana A; Rodríguez Díaz JC; Parás-Bravo P; Andrada-Becerra ME; Ruiz García MM; Rodríguez-Ingelmo JM; Portilla-Sogorb J; Paz-Zulueta M
    Cancer Prev Res (Phila); 2019 Aug; 12(8):547-556. PubMed ID: 31208965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.